MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 ,inter alia, to consider and approve unaudited financial results, standalone and consolidated, for the quarter and nine months ended December 31, 2024.

pdf

Marksans Pharma Ltd.

08 Jan 2025

174.73

-2.45%

Company Update

MARKSANS PHARMA LTD. - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Kindly find enclosed certificate under reg 74(5) of SEBI (DP) regulations

pdf

Marksans Pharma Ltd.

30 Dec 2024

174.73

-2.45%

SAST

MARKSANS PHARMA LTD. - 524404 - Closure of Trading Window

BSE India

Kindly find enclosed intimation pursuant to closure of trading window

pdf

Marksans Pharma Ltd.

11 Dec 2024

174.73

-2.45%

Company Update

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Kindly find attached

pdf

Marksans Pharma Ltd.

26 Nov 2024

174.73

-2.45%

Marksans Pharma hits new high; soars 30% in 1 month on healthy Q2 results

Business Standard

The management anticipates stronger performance in the coming quarters due to the company's upcoming new launches, the onset of the winter season and scaling up of the TEVA facility.

Marksans Pharma Ltd. is trading below all available SMAs

Marksans Pharma Ltd.

25 Nov 2024

174.73

-2.45%

Earnings Call

MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Kindly find enclosed earnings call transcript for Q2FY25 financial performance and strategy update

pdf

Marksans Pharma Ltd.

22 Nov 2024

174.73

-2.45%

Marksans Pharma gets USFDA nod for allergic rhinitis treatment tablets

Business Standard

Marksans Pharma Ltd on Friday said it has received final approval from the US health regulator for its generic version of Loratadine tablets indicated in the treatment of allergic rhinitis. The approval by the US Food and Drug Administration (USFDA) is for the company's abbreviated new drug application (ANDA) for Loratadine tablets of strength 10 mg, Marksans Pharma said in a regulatory filing. Loratadine tablets are indicated for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for over-the-counter (OTC) use. This product is a generic version of Clartin tablet in the same strength as Bayer Healthcare, the company added. Loratadine is an antihistamine that treats symptoms such as itching, runny nose, watery eyes, and sneezing from "hay fever" and other allergies, it added.